Caris Life Sciences Q2 Earnings Call Highlights
Caris Life Sciences (NASDAQ:CAI) reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization. The company completed approximately 59,200 clinical cases during the quarter ended June 30, up 18% year […]
8 Aug 16:05 · The Cerbat Gem